Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Diabetics React Less to COVID-19 Vaccinations Without Increased Risk of Break-through Infections: An Observational Study from Community Reporters
ABSTRACT
Background:
This exploratory study compares COVID-19 vaccine side effects and breakthrough infections in diabetics and non-diabetics using patient-reported data and pharmacy claims.
Objective:
The study aims to use patient reported data to evaluate differences in COVID-19 vaccine side effects between diabetic and non-diabetic adults.
Methods:
Adults who voluntarily self-enrolled between March 19, 2021 and July 16, 2022 in the IQVIA COVID-19 Active Research Experience (CARE) project reported clinical and demographic information, COVID-19 vaccination, test-confirmed infection(s), and consented to linkage with prescription claims which was used for sensitivity analysis of medication effects.
Results:
Diabetics (n=724) reported experiencing fewer vaccine side effects within 2 weeks of vaccination than non-diabetics (n=6,417) (mean [SD]=2.7(2.0] vs. 3.1[2.0]). Adjusted risk of having any or individual side effects was lower among diabetics, with significant reductions in fatigue and headache, but no differences in breakthrough infections over participants’ maximum follow-up time. Diabetic medication use did not consistently affect the risk of specific side effects.
Conclusions:
Diabetics reported fewer vaccine side effects than non-diabetics, with similar risk of breakthrough infection.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.